![]() ![]() In February, the Pharmaceutical Services Negotiating Committee appointed Janet Morrison as its new chief executive, who went on to negotiate the final two years of the community pharmacy contract in England. The new guidance came on the back of a plethora of cardiovascular outcome trial data in recent years and meant that people with type 2 diabetes mellitus, who also have cardiovascular disease or are at high risk of developing it, were offered a SGLT2 inhibitor in addition to metformin earlier in their treatment. The National Institute for Health and Care Excellence recommended a change in treatment for patients with type 2 diabetes mellitus. ![]() Guidance that would impact one of the largest patient groups in the UK was published. But the limited supply, short treatment window and small number of patient groups eligible to receive antivirals gave rise to concerns about whether they could really turn the tide on the pandemic.īy the end of the year, draft guidance from the National Institute for Health and Care Excellence recommended Paxlovid but not molnupiravir or remdesivir as options for treating COVID-19 in adults on the grounds that they were not cost-effective. Paxlovid became the first-line treatment choice, followed by remdesivir, with molnupiravir pushed down to a third-line option.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |